Evidence map›Paper›PMID 38702297›Full record

ArticleNature communications2024

Adjuvant-dependent impact of inactivated SARS-CoV-2 vaccines during heterologous infection by a SARS-related coronavirus.

Jacob A Dillard, Sharon A Taft-Benz, Audrey C Knight, Elizabeth J Anderson, Katia D Pressey, Breantié Parotti, Sabian A Martinez, Jennifer L Diaz, Sanjay Sarkar, Emily A Madden and 21 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Bacterial ghosts (BGs): A promising approach as candidate vaccine.World journal of microbiology & biotechnology · 2026
    Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

31 authors.

Jacob A Dillard *Department of Microbiology & Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.ORCID http://orcid.org/0000-0002-6560-1494
Sharon A Taft-Benz *Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Audrey C KnightDepartment of Pathology & Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Elizabeth J AndersonDivision of Comparative Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.ORCID http://orcid.org/0000-0001-7877-1639
Katia D PresseyDivision of Comparative Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Breantié ParottiDepartment of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Sabian A MartinezDepartment of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Jennifer L DiazDepartment of Microbiology & Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.ORCID http://orcid.org/0000-0002-8067-0420
Sanjay SarkarDepartment of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Emily A MaddenDepartment of Microbiology & Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Gabriela De la CruzPathology Services Core, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Lily E AdamsDepartment of Microbiology & Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Kenneth H DinnonDepartment of Microbiology & Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Sarah R LeistDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.ORCID http://orcid.org/0000-0002-4989-5381
David R MartinezDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Alexandra SchäferDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.ORCID http://orcid.org/0000-0002-4760-4923
John M PowersDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.ORCID http://orcid.org/0000-0002-0485-9109
Boyd L YountDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Izabella N CastilloDepartment of Microbiology & Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Noah L MoralesDepartment of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Jane BurdickDepartment of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Mia Katrina D EvangelistaPathology Services Core, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Lauren M RalphPathology Services Core, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Nicholas C PankowPathology Services Core, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Colton L LinnertzDepartment of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Premkumar LakshmananeDepartment of Microbiology & Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Stephanie A MontgomeryDepartment of Pathology & Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Martin T FerrisDepartment of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Ralph S BaricDepartment of Microbiology & Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.ORCID http://orcid.org/0000-0001-6827-8701
Victoria K BaxterDepartment of Pathology & Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. vkbaxter@txbiomed.org.ORCID http://orcid.org/0000-0003-0916-360X
Mark T HeiseDepartment of Microbiology & Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. mark_heisem@med.unc.edu.ORCID http://orcid.org/0000-0001-5829-8477

Funding

Virology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Deborah F. Tate · 1985 to 2026
$201.5M
Unlocking Zika Virus Immune Control and Pathogenesis with the Collaborative CrossU19AI100625 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI HEISE, MARK T · 2012 to 2021
$36.6M
Screening CoreU19AI109680 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI NELSON, JAY A · 2014 to 2018
$34.9M
Project 4: Computational panbetaCoV immunogen designP01AI158571 · NIAID · DUKE UNIVERSITY · PI HAYNES, BARTON F. · 2021 to 2023
$28.0M
MEDICAL SCIENTIST TRAINING PROGRAMT32GM008719 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DARVILLE, TONI, DESHMUKH, MOHANISH P · 1999 to 2023
$15.1M
Project 3: Serological Interactions with the Mucosal Innate Immune System Regulates COVID-19 Associated Tissue Damage.U54CA260543 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI WOLFGANG, MATTHEW C · 2020 to 2024
$9.8M
Respiratory Virus Vaccine and Adjuvant Exploration - Equipment SupplementU01AI149644 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BARIC, RALPH S · 2019 to 2023
$6.1M
Molecular Biology of Viral Diseases Predoctoral Training GrantT32AI007419 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Mark T Heise, CARY A MOODY · 1993 to 2026
$4.7M
Genetic Analysis of COVID-19 Susceptibility and Resistance Determinants in the Collaborative CrossR01AI157253 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BARIC, RALPH S, HEISE, MARK T · 2020 to 2024
$3.8M
Pathogenesis of and host response to chikungunya virus infection of the central nervous systemK01OD026529 · OD · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BAXTER, VICTORIA K · 2018 to 2022
$631k
Modeling chikungunya virus neuroinvasion and neuropathogenesis in miceR21NS135258 · NINDS · TEXAS BIOMEDICAL RESEARCH INSTITUTE · PI BAXTER, VICTORIA K · 2023 to 2023
$545k
NCI NIH HHS P30 CA016086NCI NIH HHS U54 CA260543NIAID NIH HHS P01 AI158571NIAID NIH HHS R01 AI157253NIAID NIH HHS T32 AI007419NIAID NIH HHS U01 AI149644NIAID NIH HHS U19 AI100625NIAID NIH HHS U19 AI109680NIGMS NIH HHS T32 GM008719NIH HHS K01 OD026529NINDS NIH HHS R21 NS135258ODCDC CDC HHS K01 OD026529
6 · The paper itself

Abstract

Whole virus-based inactivated SARS-CoV-2 vaccines adjuvanted with aluminum hydroxide have been critical to the COVID-19 pandemic response. Although these vaccines are protective against homologous coronavirus infection, the emergence of novel variants and the presence of large zoonotic reservoirs harboring novel heterologous coronaviruses provide significant opportunities for vaccine breakthrough, which raises the risk of adverse outcomes like vaccine-associated enhanced respiratory disease. Here, we use a female mouse model of coronavirus disease to evaluate inactivated vaccine performance against either homologous challenge with SARS-CoV-2 or heterologous challenge with a bat-derived coronavirus that represents a potential emerging disease threat. We show that inactivated SARS-CoV-2 vaccines adjuvanted with aluminum hydroxide can cause enhanced respiratory disease during heterologous infection, while use of an alternative adjuvant does not drive disease and promotes heterologous viral clearance. In this work, we highlight the impact of adjuvant selection on inactivated vaccine safety and efficacy against heterologous coronavirus infection.

Indexed as

Aluminum HydroxideCOVID-19COVID-19 VaccinesSARS-CoV-2Vaccines, InactivatedAdjuvants, ImmunologicAdjuvants, VaccineAnimalsAntibodies, ViralDisease Models, AnimalFemaleHumansMiceMice, Inbred BALB CSevere acute respiratory syndrome-related coronavirusAdjuvants, ImmunologicAdjuvants, VaccineAluminum HydroxideAntibodies, ViralCOVID-19 VaccinesSARS-CoV-2 inactivated vaccinesVaccines, Inactivated

Identifiers

PMID38702297
PMCPMC11068739

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.